בסייד
What is ketamine?
Ketamine treatment for depression, marketed under the brand name Spravato, refers specifically to esketamine nasal spray therapy. Esketamine is a form of ketamine that has been developed for intranasal administration and is used in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).
Spravato (esketamine) nasal spray received FDA approval in March 2019 for use in conjunction with an oral antidepressant for adults with TRD. This approval was based on clinical trials demonstrating the rapid onset of antidepressant effects of esketamine compared to placebo.
​
​Esketamine, like ketamine, is an N-methyl-D-aspartate (NMDA) receptor antagonist. Its exact mechanism of action in treating depression is not fully understood, but it's believed to involve modulation of glutamate neurotransmission and synaptic plasticity.
​
Reasons why Ketamine (Spravato) treatment for depression might be considered:
Rapid Onset of Antidepressant Effects: Ketamine (Spravato) treatment has shown the potential for rapid onset of antidepressant effects, often within hours or days of administration. This is particularly beneficial for individuals with severe depression who may not respond to traditional antidepressant medications, which can take weeks or months to show significant improvement. The ability to experience relief from depressive symptoms more quickly can lead to improved functioning and a reduction in the risk of self-harm or suicide.
​
Treatment for Treatment-Resistant Depression: Ketamine (Spravato) treatment is specifically indicated for adults with treatment-resistant depression (TRD), meaning they have not responded adequately to other antidepressant medications. For individuals who have tried multiple antidepressants without success, ketamine therapy offers a novel approach that may provide relief when other options have failed. This can be particularly valuable for improving the quality of life and functioning in individuals who have struggled with persistent depressive symptoms.
